Radiation-induced xerostomia in patient with head and neck cancer underwent radiotherapy Radiation-induced xerostomia, xerostomia, head and neck cancer, radiotherapy, pilocarpine
Conditions
Interventions
During phase I of the trial, pilocarpine 5 mg tablets (in sealed envelop) will be given to the patient for a total of 42 tablets. The patient will be instructed to take the medication in as needed dos
Sponsors
Ratchadapisek Pageant Research Fund
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years old and above 2. Diagnosed with head and neck cancer 3. Underwent radiotherapy (IMRT or 3D-CRT technique) more than 6 months prior to entering this study 4. History of xerostomia 5. Clinical Oral Dryness Score 3 and above 6. Can understand Thai 7. Able to attend follow-up visits 8. Consent to be in the study
Exclusion criteria
Exclusion criteria: 1. Pilocarpine allergy 2.Autoimmune disease 3.Patient with current medications affecting salivary flows 4. Patient with swallowing proble or currently using nasogastric tube feeding 5.Patient with current use of pilocarpine or other sialogogue within 1 month prior to the study 6. Pregnant woman and lactating woman 7. Patient underwent oral surgery and salivary gland surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Xerostomia Inventory Phase I: pre and post treatment, Phase II: pre and post treatment Xerostomia Inventory Questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects Everyday during phase I and II Patient reported adverse effects using a case record form | — |
Countries
Thailand
Contacts
Public ContactNatcha Watapokasin
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed